Brought to you by 
Oxford Immunotec Global PLC nets $68.8mm via IPO
27 Apr 2021
Executive Summary
UK-based Oxford Immunotec Global PLC (develops diagnostics that measure effector T-cell response to certain antigens) netted $68.8mm in its initial public offering of 6.16mm ordinary shares (including the overallotment) at $12 on Nasdaq. The company originally thought it would sell the shares between $13 and $15.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Cytology
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oxford Immunotec Global PLC nets $68.8mm via IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice